Sign in Subscribe
Cancer research

CRISPR Gene Editing Revolutionizes Cancer Research

Strategic Insights

— 1 min read

Researchers from the University of Toronto have published a new study on the impact of CRISPR gene editing on cancer research. According to the study, CRISPR tools are transforming the field of oncology by enabling the creation of cancer models, studying tumor evolution, and identifying genes involved in cancer growth and chemosensitivity. The study highlights the potential of CRISPR technology in developing new cancer therapies, including chimeric antigen receptor T cells and precision anticancer gene-editing agents.

Key Takeaways:

  • CRISPR gene editing tools are revolutionizing cancer research by enabling the establishment of genotype-phenotype relationships and transforming cell- and gene-based therapies.
  • In oncology, CRISPR/Cas9, Cas12, and Cas13 have advanced the generation of cancer models, the study of tumor evolution, and the identification of target genes involved in cancer growth.
  • Preclinical therapeutic strategies employing CRISPR/Cas have emerged, including the generation of chimeric antigen receptor T cells and engineered immune cells.
  • CRISPR/Cas has shown promise in inactivating driver oncogenes, suppressing tumor support genes, and culling cancer cells in response to genetic circuit output.
  • The study highlights the promise and challenges facing the clinical translation of CRISPR technology in cancer research.
  • The research emphasizes the importance of understanding the collective impact of CRISPR technology on basic and applied cancer research.
  • The study emphasizes the potential of CRISPR technology in developing new cancer therapies, including precision anticancer gene-editing agents.

Statistics:

  • According to the study, CRISPR/Cas9, Cas12, and Cas13 have advanced the generation of cancer models, enabling the study of tumor evolution and identifying genes involved in cancer growth.
  • The study highlights the potential of CRISPR technology in developing new cancer therapies, including chimeric antigen receptor T cells and precision anticancer gene-editing agents.
  • The report states that the research has been peer-reviewed.
  • The study emphasizes the collective impact of CRISPR technology on basic and applied cancer research.
  • The study highlights the promises and challenges facing the clinical translation of CRISPR technology in cancer research.

Sources:

  • Crispr/cas Technologies for Cancer Drug Discovery and Treatment. Trends in Pharmacological Sciences, 2025;46(5):437-452.
  • University of Toronto. Dept. of Pharmacology and Toxicology, Toronto, On M5S 1A8, Canada. (Basil P. Hubbard, Kevin C. Wang, and Tiffany Zheng)
  • NewsRx LLC. Cancer Weekly. July 1, 2025; p 70.

Read more